Marshall Wace
TPST icon

Marshall Wace’s Tempest Therapeutics TPST Stock Holding History

Marshall Wace’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4
Closed -$79K – 1118
2016
Q3 		$79K Sell
4
-81
-95% -$1.47M ﹤0.01% 908
2016
Q2 		$1.29M Buy
+85
New +$1.94M 0.01% 674

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace's TPST Position: Q4 2016 in Review

Marshall Wace sold out of Tempest Therapeutics (TPST) in Q4 2016, closing a stake of 4 shares — an estimated $79K sold.

Marshall Wace first reported a position in TPST in Q2 2016 and held it in 2 quarters. The position peaked at $1.29M in Q2 2016. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

  • Marshall Wace reported no remaining Tempest Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Marshall Wace sold 4 Tempest Therapeutics shares in Q4 2016, an estimated $79K.
  • Marshall Wace first reported a position in Tempest Therapeutics in Q2 2016 and held it in 2 quarters.
  • Marshall Wace's Tempest Therapeutics position peaked at $1.29M in Q2 2016.
  • 84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on Marshall Wace's 13F filing for Q4 2016, filed 10 Feb 2017.